Moneycontrol PRO
granules india
Jump to
380 Results Found
  • Drug makers Granules India, Jubilant Cadista recall products in US market Sep 12, 2021 09:11 PM IST

    Drug makers Granules India, Jubilant Cadista recall products in US market

    As per the latest Enforcement Report by US Food and Drug Administration (USFDA), the US-based unit of Granules India is recalling over 1.14 crore Naproxen Sodium tablets, a non-steroidal anti-inflammatory drug used to treat pain, menstrual cramps, inflammatory diseases such as rheumatoid arthritis, gout and fever.

  • Granules India gets licence from DRDO to manufacture and market COVID-19 drug Sep 02, 2021 07:36 PM IST

    Granules India gets licence from DRDO to manufacture and market COVID-19 drug

    Developed by DRDO, 2-DG has been granted permission by Drug Controller General of India (DCGI) for emergency use as adjunct therapy in moderate to severe COVID-19 patients, Granules India said in a filing to BSE.

  • Granules India gets Health Canada nod to market arthritis tablets Aug 30, 2021 01:51 PM IST

    Granules India gets Health Canada nod to market arthritis tablets

    The company has received approval from Health Canada for Acetaminophen extended-release tablets OTC, 650 mg, Granules India said in a regulatory filing.

  • Buy Granules India; target of Rs 430: ICICI Direct Aug 04, 2021 05:30 PM IST

    Buy Granules India; target of Rs 430: ICICI Direct

    ICICI Direct is bullish on Granules India has recommended buy rating on the stock with a target price of Rs 430 in its research report dated July 29, 2021.

  • Buy Granules India; target of Rs 459: KR Choksey Aug 04, 2021 02:17 PM IST

    Buy Granules India; target of Rs 459: KR Choksey

    KR Choksey is bullish on Granules India has recommended buy rating on the stock with a target price of Rs 459 in its research report dated July 28, 2021.

  • Dr Reddy’s: Growth story remains intact; margins key monitorable Jul 28, 2021 11:43 AM IST

    Dr Reddy’s: Growth story remains intact; margins key monitorable

    Dr Reddy's margins are likely to be weighed by recurring investments - digitization, brand building exercise & elevated R&D - in near to medium term

  • Granules India Consolidated June 2021 Net Sales at Rs 849.85 crore, up 15.53% Y-o-Y Jul 27, 2021 07:22 PM IST

    Granules India Consolidated June 2021 Net Sales at Rs 849.85 crore, up 15.53% Y-o-Y

  • Granules India Standalone June 2021 Net Sales at Rs 732.12 crore, down 1.45% Y-o-Y Jul 27, 2021 07:11 PM IST

    Granules India Standalone June 2021 Net Sales at Rs 732.12 crore, down 1.45% Y-o-Y

  • Granules India concludes COVID-19 vaccine drive for all its employees in India Jul 13, 2021 02:17 PM IST

    Granules India concludes COVID-19 vaccine drive for all its employees in India

    The on-premises vaccination drive was conducted in association with government authorised hospitals and the vaccines were administered to over 4,500 employees as per the government approved protocols, Granules India said in a statement.

  • Granules India Q1 PAT seen up 54.7% YoY to Rs 99.2 cr: KRChoksey Jul 13, 2021 11:55 AM IST

    Granules India Q1 PAT seen up 54.7% YoY to Rs 99.2 cr: KRChoksey

    Net Sales are expected to decrease by 9.5 percent Y-o-Y (down 22.4 percent Q-o-Q) to Rs 666 crore, according to KRChoksey.

  • Bulk Deals | BNP Paribas buys 12.52 lakh shares in Granules, Navodya Enterprises 1.26 lakh shares in SML Isuzu Jul 12, 2021 11:18 PM IST

    Bulk Deals | BNP Paribas buys 12.52 lakh shares in Granules, Navodya Enterprises 1.26 lakh shares in SML Isuzu

    AEP Green Power sold 1,50,65,290 equity shares on the NSE, and 1,45,00,000 equity shares in Orient Green Power on the BSE, at Rs 3.01 per share.

  • Granules India shares jumps 2% after company denies reports of being sold to PE investors Jul 12, 2021 10:59 AM IST

    Granules India shares jumps 2% after company denies reports of being sold to PE investors

    The company has slammed as "utterly false and malicious" messages floating around on social media about the firm being sold to some PE investors.

  • Bulk Deals | Porinju Veliyath sells 0.6% stake in Sandu Pharma, BNP Paribas buys 1.15% in Granules Jul 09, 2021 09:23 PM IST

    Bulk Deals | Porinju Veliyath sells 0.6% stake in Sandu Pharma, BNP Paribas buys 1.15% in Granules

    Rajendra Y Shah sold 2.22 lakh equity shares in Megasoft at Rs 16.26 per share on the NSE, while Ashok Kumar Chaudhary offloaded 46 lakh equity shares in Sanwaria Consumer at Rs 0.8 per share.

  • Small & Midcap Mantra: Granules India on track to test record highs Jun 09, 2021 12:48 PM IST

    Small & Midcap Mantra: Granules India on track to test record highs

    With a market cap of more than Rs 8,000 crore, the stock has been an underperformer. It hit the all-time high of Rs 437.95 in December 2020. The stock is set to test this level in 2-3 months

  • Granules India Q4 net profit up 38% at Rs 128 crore May 11, 2021 10:10 PM IST

    Granules India Q4 net profit up 38% at Rs 128 crore

    The company had posted a net profit of Rs 92.33 crore for the corresponding period of the previous fiscal.

  • Granules India Consolidated March 2021 Net Sales at Rs 799.31 crore, up 33.24% Y-o-Y May 11, 2021 08:44 PM IST

    Granules India Consolidated March 2021 Net Sales at Rs 799.31 crore, up 33.24% Y-o-Y

  • Granules India Standalone March 2021 Net Sales at Rs 781.55 crore, up 60.53% Y-o-Y May 11, 2021 08:33 PM IST

    Granules India Standalone March 2021 Net Sales at Rs 781.55 crore, up 60.53% Y-o-Y

  • Buy Granules India: target of Rs 475: Sharekhan Mar 18, 2021 02:00 PM IST

    Buy Granules India: target of Rs 475: Sharekhan

    Sharekhan is bullish on Granules India has recommended buy rating on the stock with a target price of Rs 475 in its research report dated March 16, 2021.

  • Buy Granules India; target of Rs 460: ICICI Direct Feb 04, 2021 05:22 PM IST

    Buy Granules India; target of Rs 460: ICICI Direct

    ICICI Direct is bullish on Granules India has recommended buy rating on the stock with a target price of Rs 460 in its research report dated January 29, 2021.

  • Buy Granules India; target of Rs 460: Motilal Oswal Feb 03, 2021 08:48 PM IST

    Buy Granules India; target of Rs 460: Motilal Oswal

    Motilal Oswal is bullish on Granules India has recommended buy rating on the stock with a target price of Rs 460 in its research report dated January 28, 2021.

  • Granules arm gets USFDA nod for Potassium Chloride Oral Solution Feb 01, 2021 11:09 AM IST

    Granules arm gets USFDA nod for Potassium Chloride Oral Solution

    The approved product is bioequivalent to the reference listed drug Potassium Chloride Oral Solution of Genus Lifesciences, Inc.

  • Buy Granules India; target of Rs 475: Sharekhan Jan 29, 2021 07:13 PM IST

    Buy Granules India; target of Rs 475: Sharekhan

    Sharekhan is bullish on Granules India has recommended buy rating on the stock with a target price of Rs 475 in its research report dated January 28, 2021.

  • Granules India Standalone December 2020 Net Sales at Rs 776.01 crore, up 25.89% Y-o-Y Jan 29, 2021 09:22 AM IST

    Granules India Standalone December 2020 Net Sales at Rs 776.01 crore, up 25.89% Y-o-Y

  • Granules India Consolidated December 2020 Net Sales at Rs 844.51 crore, up 19.97% Y-o-Y Jan 29, 2021 09:22 AM IST

    Granules India Consolidated December 2020 Net Sales at Rs 844.51 crore, up 19.97% Y-o-Y

  • Granules India share price up 3% on USFDA approval Jan 13, 2021 12:48 PM IST

    Granules India share price up 3% on USFDA approval

    The share touched its 52-week high Rs 438.00 and 52-week low Rs 114.50 on 01 December, 2020 and 23 March, 2020, respectively.

Sections
ISO 27001 - BSI Assurance Mark